Newly approved treatments for patients with posttraumatic stress disorder are lacking. Ketamine and cannabinoids could offer hope.
July 2018
The FDA's approval of erenumab marked a milestone in migraine treatment, and although the calcitonin gene-related peptide inhibitor class is full of promise, it has overcome many pitfalls along the way.
Advertisement
Advertisement
Trending on HCPLive
1
Navigating Emotional Burden in IBD
2
Highlighting FDA-Approved Therapies in Atopic Dermatitis, With Chris Bunick, MD, PhD
3
Open Communication Between Patients and Providers in IBD
4
Linaclotide in Pediatric IBS-C—Evidence, Indications, and Practical Use
5